- Home
- Publications
- Publication Search
- Publication Details
Title
Combining Radiotherapy and Immunotherapy in Head and Neck Cancer
Authors
Keywords
-
Journal
Biomedicines
Volume 11, Issue 8, Pages 2097
Publisher
MDPI AG
Online
2023-07-26
DOI
10.3390/biomedicines11082097
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity
- (2022) Kathryn M. Tully et al. CLINICAL CANCER RESEARCH
- Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
- (2022) Elizabeth A. Mittendorf et al. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
- LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)
- (2022) J-P. Machiels et al. ANNALS OF ONCOLOGY
- Radiotherapy with Durvalumab vs. Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer and a Contraindication to Cisplatin: Phase II Results of NRG-HN004
- (2022) L.K. Mell et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges
- (2021) Jack M. Qian et al. Frontiers in Oncology
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2021) Nancy Y Lee et al. LANCET ONCOLOGY
- Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis
- (2021) Yimin Xu et al. Frontiers in Immunology
- LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial
- (2021) J. Bourhis et al. ANNALS OF ONCOLOGY
- Clinico-pathological peculiarities of human papilloma virus driven head and neck squamous cell carcinoma: A comprehensive update
- (2020) K Devaraja et al. LIFE SCIENCES
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
- (2020) Sean McBride et al. JOURNAL OF CLINICAL ONCOLOGY
- Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Single-institution outcomes
- (2019) James E. Bates et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.
- (2019) Ravindra Uppaluri et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
- (2019) Pierluigi Bonomo et al. ORAL ONCOLOGY
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
- (2019) Jay Friedman et al. CLINICAL CANCER RESEARCH
- Impact of PD‐L1 expression and human papillomavirus status in anti‐PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma—Systematic review and meta‐analysis
- (2019) Jaimin J. Patel et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC
- (2018) Xu Shan Sun et al. Future Oncology
- PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome
- (2018) Sven Schneider et al. HISTOPATHOLOGY
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
- (2018) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
- (2018) Yifan Wang et al. Frontiers in Pharmacology
- 1117TiPIMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)
- (2018) R Haddad et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands
- (2017) Japke F. Petersen et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141
- (2017) Naomi Kiyota et al. ORAL ONCOLOGY
- Radiotherapy combination opportunities leveraging immunity for the next oncology practice
- (2016) Fernanda G. Herrera et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?
- (2015) Stuart E. Samuels et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Epidemiology of Head and Neck Cancer
- (2015) Eleni M. Rettig et al. Surgical Oncology Clinics of North America
- Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma
- (2014) Carole Fakhry et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
- (2014) S. Matsumura et al. JOURNAL OF IMMUNOLOGY
- Long-term Follow-up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck
- (2012) Jay S. Cooper et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy
- (2010) A M Hong et al. BRITISH JOURNAL OF CANCER
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Head and neck cancer
- (2008) Athanassios Argiris et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started